Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...
Many investors view the healthcare sector as a safe haven when the stock market is turbulent. Here are three no-brainer ...
UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis: London Monday, March 10, 2025, 10:00 Hrs [IST] Vertex Pharmaceuticals, a ...
The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...
There are hundreds of publicly traded companies on various equity markets worldwide. Investors choose to put their ...
Now squarely in 2025, we continue to extend our leadership in CF, notably with the recent approval and ongoing launch of ALYFTREK. We are continuing to build momentum with CASGEVY, our gene ...
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
It recently won two key U.S. Food and Drug Administration (FDA) approvals, one for CF therapy Alyftrek and another for acute pain drug Journavx (suzetregine). Alyftrek is Vertex's most powerful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback